The short version of prothymosin alpha fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-07-03 and is reviewed periodically as new material appears.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | 28 residues; not a small-molecule compound |
| Molecular mass | About 3,106 Da | Monoisotopic mass of the unmodified chain |
| N-terminal group | Acetylated serine | Present in both native and synthetic forms |
| Secondary structure | Disulfide-constrained loop | One bridge between two cysteine residues |
| Typical source | Solid-phase synthesis | Early isolates came from bovine thymus extracts |
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Cuellar, Francisco Ramírez; Aviva Chomsky (2005). The Profits of Extermination. Monroe, ME: Common Courage Press. ISBN 1-56751-322-0. Aviva Chomsky (2008). Linked labor histories: New England, Colombia, and the making of a global working class. Duke University Press. ISBN 978-0-8223-4190-1. Bushnell, David (1993). The Making of Modern Colombia, a Nation in spite of itself. University of California Press. ISBN 0-520-08289-3. Dudley, Steven (January 2004). Walking Ghosts: Murder and Guerrilla Politics in Colombia. Routledge. ISBN 0-415-93303-X. Kirk, Robin (January 2003). More Terrible than Death: Massacres, Drugs, and America's War in Colombia. PublicAffairs. ISBN 1-58648-104-5. Meernik, DeMerritt and Uribe-Lopez (eds.). 2019. As War Ends: What Colombia Can Tell Us About the Sustainability of Peace and Transitional Justice. Cambridge University Press. Ruiz, Bert (October 1, 2001). The Colombian Civil War. McFarland & Company. ISBN 0-7864-1084-1. Safford, Frank; Marco Palacios (July 1, 2001). Colombia: Fragmented Land, Divided Society. Oxford University Press. ISBN 0-19-504617-X. Steele, Abbey. 2018. Democracy and Displacement in Colombia's Civil War. Cornell University Press. Stokes, Doug (2005). America's Other War: Terrorizing Colombia. Noam Chomsky (Foreword). Zed Books. ISBN 1-84277-547-2. Taussig, Michael (November 1, 2003). Law in a Lawless Land: Diary of a Limpieza. New Press. ISBN 1-56584-863-2. Books in other languages
== History == In 1799, British chemist Charles Hatchett experimented with decalcifying the shells of various crustaceans, finding that a soft, yellow and cartilage-like substance was left behind that is now known to be chitin. In 1859, French physiologist Charles Marie Benjamin Rouget found that boiling chitin in potassium hydroxide solution could deacetylate it to produce a substance that was soluble in dilute organic acids, that he called chitine modifiée. In 1894, German chemist Felix Hoppe-Seyler named the substance chitosan. From 1894 to 1930 there was a period of debate and confusion over the exact composition of chitin and particularly whether animal and fungal forms were the same chemicals. In 1930 the first chitosan films and fibres were patented but competition from petroleum-derived polymers limited their uptake. It was not until the 1970s that there was renewed interest in the compound, spurred partly by laws that prevented the dumping of untreated shellfish waste.
=== Desalination of sea water === Work by Viviane Renaudin has led to the development of a new type of multiple-effect plate evaporator, which can be used for the desalination of brackish or sea water. The proposed distillation process is based on the principle of multiple-effect dripping film plate evaporators. The innovation lies in the horizontal transfer of vapour to the condensation zone. From a socio-economic point of view, thanks to its human-scale dimensions, its modular construction and its ease of assembly, the system has the advantage of being usable by unskilled operators in developing countries. The process also has political value: it enables countries to end their dependence on their neighbours for their drinking water supplies.
Sources: en.wikipedia.org
On 17 July 2007, following a four-year inquiry, the House of Commons Select Committee on Standards and Privileges published its sixth report. The Parliamentary Commissioner for Standards, in an addendum to the report, concluded that there was no evidence that Galloway gained any personal benefit from either the former Iraqi administration, or from the Oil-for-Food Programme, but admitted that some documents had been unavailable to him. However, the Committee concluded, in the main body of the report:
Medea resolves to kill her own children as well, not because the children have done anything wrong, but because she feels it is the best way to hurt Jason. She calls for Jason once more and, in an elaborate ruse, apologizes to him for overreacting to his decision to marry Glauce. When Jason appears fully convinced that she regrets her actions, Medea begins to cry in mourning of the exile. She convinces Jason to allow their two sons to give gifts to Glauce in hopes that Creon will lift the exile against the children. Eventually Jason agrees.
== Applications and examples == Exponential decay occurs in a wide variety of situations. Most of these fall into the domain of the natural sciences. Many decay processes that are often treated as exponential, are really only exponential so long as the sample is large and the law of large numbers holds. For small samples, a more general analysis is necessary, accounting for a Poisson process.
Sources: en.wikipedia.org
Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.
The single bridge between two cysteine residues holds the chain in a folded loop that influences its shape and its behavior in solution. Loss of the bridge through reduction or oxidation shifts chromatographic retention and is tracked during stability work.
It is a defined 28-residue sequence derived from a larger precursor, whereas many other thymic preparations are mixtures of several polypeptides. Its acetylated amino terminus and single disulfide bridge distinguish it chemically from unrelated thymic extracts.
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.